Plandai Biotechnology Inc (OTCMKTS:PLPL) has announced that its flagship bioavailable Phytofare Catechin Complex will be used by USN for the development of a new range of green-tea based products. According to a recent statement, this announcement is a result of the expansion of product distribution deal between USN and Plandai. The product will initially be made available in Australia and New Zealand markets.

Road So Far

With an objective to cater a large marketplace, both the companies have been working with each other for some time. The previous deal between both of them prompted USN to use Phytofare Catechin in all the green tea based products that are sold and manufactured in Europe and South Africa. Since the previous deal brought a great result, both of them want to cater a bigger marketplace and see if their association is fruitful or not.

As part of their latest deal, USN will contact its distributor contractors and ask them to enhance the reach of Phytofare in Australia and New Zealand. The senior management teams of both the companies are super excited after this deal and hope that it will help them achieve desired results.

Meanwhile Metabolix, Inc. (NASDAQ:MBLX) has announced the launch of its highly awaited project Yield10 Bioscience for the development of innovative concepts in crop science and commercialize them on a large scale. Through this project, Metabolix intends to address the growing need for food production, which is likely to become a major issue by 2050 when the global population surpasses 9 billion.

With an objective to enhance the reach of its product AcnEase, Herborium Group, Inc. (OTCMKTS:HBRM) has decided to launch multiple websites equipped with a wide range of world-class features. These websites cater audience from the US as well as other countries. The launch of these websites is part of a huge promotional plan that the company had started in June 2015. The promotion is likely to continue until the end of the year.